United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Osteocalcin (OST) ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:OST, bone Gla protein, B.G.P
  • Species:Human
Cat. No. Size Price

RIS002R 96 wells (1 kit) $493,49
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody


The RIS002R Human Osteocalcin ELISA Immunoenzymetric assay for the measurement of intact human osteocalcin (OST) in serum. It is intended for research use only.



Sample Requirements

25 µl/well


On blue ice packs. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

1.56–75 ng/ml

Limit of Detection

0.08 ng/ml

Intra-assay (Within-Run)

CV < 6%

Inter-assay (Run-to-Run)

CV < 6%



  • RUO
  • calibration range 1.56-75 ng/ml
  • limit of detection 0.08ng/ml
  • quality controls

Research topic

Bone and cartilage metabolism


Biological activities

Osteocalcin or bone Gla protein (B.G.P) is the major non-collagen protein of the bone matrix. It has a molecular weight of 5800 Da and contains 49 amino-acids, including 3 residues of gamma carboxyl glutamic acid. Osteocalcin is synthesized in the bone by the osteoblasts. After production, it is partly incorporated in the bone matrix and the rest is found in the blood circulation. The exact physiological function of osteocalcin is still unclear. A large number of studies show that the circulating levels of osteocalcin reflect the rate of bone formation.

Clinical application

The determination of the blood levels of osteocalcin is valuable for : − The identification of women at risk of developing osteoporosis − Monitoring bone metabolism during the perimenopause and postmenopause − Monitoring bone metabolism during hormone replacement therapy and treatment of premenopausal women with LH-RH agonists − Monitoring bone metabolism in patients with growth hormone deficiency, hypothyroidism, hyperthyroidism, chronic renal failure.

Summary References (8)

References to Osteocalcin

  • Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984 May 19;1 (8386):1091-3
  • Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, Rubens RD. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol. 1988 Jul;24 (7):1211-7
  • Coulton LA, Preston CJ, Couch M, Kanis JA. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment. Arthritis Rheum. 1988 Sep;31 (9):1142-7
  • Demiaux B, Arlot ME, Chapuy MC, Meunier PJ, Delmas PD. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab. 1992 May;74 (5):1146-51
  • Johansen JS, Jensen SB, Riis BJ, Rasmussen L, Zachmann M, Christiansen C. Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. J Clin Endocrinol Metab. 1990 Jul;71 (1):122-6
  • Minisola S, Scarnecchia L, Scarda A, Bigi F, Tabolli S, Valtorta C, Mazzuoli G. Serum osteocalcin in primary hyperparathyroidism: short-term effect of surgery. Miner Electrolyte Metab. 1988;14 (4):201-7
  • Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci. 1991;28 (4):287-335
  • Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm. 1985;42:65-108
Related Products Docs